337 related articles for article (PubMed ID: 27665574)
21. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
22. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
[TBL] [Abstract][Full Text] [Related]
23. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
[TBL] [Abstract][Full Text] [Related]
24. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
25. Safinamide: from molecular targets to a new anti-Parkinson drug.
Caccia C; Maj R; Calabresi M; Maestroni S; Faravelli L; Curatolo L; Salvati P; Fariello RG
Neurology; 2006 Oct; 67(7 Suppl 2):S18-23. PubMed ID: 17030736
[TBL] [Abstract][Full Text] [Related]
26. Safinamide for the treatment of Parkinson's disease.
deSouza RM; Schapira A
Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
[TBL] [Abstract][Full Text] [Related]
27. ▼ Safinamide for Parkinson's disease.
Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
[TBL] [Abstract][Full Text] [Related]
28. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
29. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
Dezsi L; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Kurihara K; Mishima T; Fujioka S; Tsuboi Y
Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
[TBL] [Abstract][Full Text] [Related]
31. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
[TBL] [Abstract][Full Text] [Related]
32. Safinamide: A Review in Parkinson's Disease.
Blair HA; Dhillon S
CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
[TBL] [Abstract][Full Text] [Related]
34. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Abdelalem Aziz Ahmed M
F1000Res; 2019; 8():2078. PubMed ID: 32431802
[No Abstract] [Full Text] [Related]
35. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
[TBL] [Abstract][Full Text] [Related]
36. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Chazot PL
Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
[TBL] [Abstract][Full Text] [Related]
37. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Cattaneo C; Jost WH; Bonizzoni E
J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
[TBL] [Abstract][Full Text] [Related]
39. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Müller T; Riederer P; Grünblatt E
Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
[TBL] [Abstract][Full Text] [Related]
40. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Perez-Lloret S; Rascol O
Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
